Table 2 Uni- and multivariate analysis of predictive factors for overall survival in patients undergoing surgical resection after neoadjuvant therapy
Number | Median survival (95% CI) | p value by log-rank test | p value by Cox proportional hazards | Hazard ratio (95% CI) | |
|---|---|---|---|---|---|
Gender | |||||
Male | 119 | 32.7 (27.3–58.3) | |||
Female | 121 | 35.7 (26.9–40.6) | 0.821 | ||
Pre-neoadjuvant therapy CA19–9 value (U/ml) | |||||
> 103 U/ml | 147 | 28 (23.5–32.9) | 1.711 | ||
≤ 103 U/ml | 93 | 40 (33.2-) | 0.001 | 0.010 | (1.133–2.639) |
Pre-neoadjuvant therapy tumor size (mm) | |||||
> 27 | 116 | 29.3 (23.3–34.9) | 1.517 | ||
≤ 27 | 124 | 36.1 (30.1–115.7) | 0.015 | 0.040 | (1.018–2.278) |
Location | |||||
Ph | 160 | 32.9 (26.7–36.9) | |||
Pbt | 80 | 34.9 (27.3-) | 0.325 | ||
Neoadjuvant therapy | |||||
Systematic chemotherapy | 115 | 35.7 (30.7–58.3) | |||
Chemoradiotherapy | 125 | 30.2 (27.3–40.6) | 0.550 | ||
NCCN Resectability | |||||
Resectable | 132 | 38.7 (33.9–99.2) | 1.471 | ||
Borderline | 108 | 24.8 (19.9–30.7) | < 0.0001 | 0.063 | (0.979–2.219) |
RESICT | |||||
Other than progressive disease | 236 | 33.2 (29.3–38.7) | 3.930 | ||
Progressive disease | 4 | 17.6 (12.8–18.7) | 0.023 | 0.064 | (0.912–11.740) |
Duration of neoadjuvant therapy (day) | |||||
> 69 | 109 | 35.7 (28.3–50) | |||
≤ 69 | 131 | 32.7 (24.9–38.7) | 0.413 | ||
Operative procedure | |||||
Pancreaticoduodenectomy | 160 | 32.9 (26.7–36.9) | |||
Distal pancreatectomy | 80 | 34.9 (27.3-) | 0.325 | ||
N classification | |||||
1 | 130 | 23.9 (20.4–32.9) | 1.905 | ||
0 | 110 | 40 (32.7–99.2) | < 0.0001 | 0.002 | (1.276–2.875) |
R status | |||||
1 | 35 | 19.9 (17.5–30.7) | 1.659 | ||
0 | 205 | 35.9 (30.1–41.7) | 0.002 | 0.045 | (1.012–2.627) |
Adjuvant therapy | |||||
yes | 205 | 32.9 (29.3–38.7) | |||
no | 35 | 28.6 (15.2–83.1) | 0.360 | ||